Intervention
CSU subjects were treated with a single subcutaneous dose of placebo at
visit 1, followed by three subcutaneous doses of benralizumab 30 mg at
4-week intervals (visits 2, 3, and 4). The non-CSU subjects, recruited
for comparison blood and skin biopsy control samples, received no
treatment.